Lexeo Therapeutics director gets 70,000-share option grant
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Lexeo Therapeutics, Inc. (LXEO) director Tobin Schilke received an option grant covering 70,000 shares of common stock on November 14, 2026, at an exercise price of $2.87 per share. One-third of the underlying shares vests and becomes exercisable on each yearly anniversary of the grant date; all are scheduled to be vested and exercisable on November 14, 2029, subject to continuous service on each vesting date. The options expire on November 13, 2036.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 70,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. 1/3rd of the shares underlying the option shall vest, and become exercisable, on each yearly anniversary of the Grant Date, such that all shares are vested and exercisable on November 14, 2029, subject to the Reporting Person's continuous service on each such vesting date.
Key Figures
Key Terms
Stock Option (right to buy) technical
vest technical
exercisable technical
continuous service technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did LXEO director Tobin Schilke receive, and what is the exercise price?
When do Tobin Schilke’s LXEO options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.